CONGRESS SPEAKERS

COMING SOON

Dr. Basaria is an internationally recognized reproductive endocrinologist with expertise in sex-steroid biology, endocrine complications of androgen deprivation therapy in men with prostate cancer, and association of sex steroids with pain perception and pain tolerance. He is also an expert clinical trialist and has designed numerous clinical trials that are known for their novel design. Most of his clinical trials have focused on the effects of androgen replacement in men and women where he has evaluated various efficacy outcomes such as sexual function, fatigue, quality of life and physical function. He is also an expert on the risks of androgen replacement, in particular cardiometabolic disease. Dr. Basaria has over 200 peer-reviewed manuscripts, 30 book chapters and over 250 abstracts. His group was the first to report that testosterone replacement improves pain perception, sexual function and quality of life in men with opioid-induced androgen deficiency. His group was also the first to report metabolic adverse effects of androgen deprivation in men with prostate cancer. He has also conducted several epidemiological studies in collaboration with investigators from the Baltimore Longitudinal Study of Aging, the InChianti Study and the Framingham Heart Study evaluating the role of sex steroids on inflammatory markers and metabolism.

In addition to his own active research program, he is also the Associate Director of the Section of Men’s Health, Aging and Metabolism Unit at the Brigham and Women’s Hospital. In this capacity, he oversees several trials examining the effect of testosterone replacement on vitality, physical function and quality of life.

He received his MBBS from the Aga Khan University Medical School in Karachi, Pakistan; residency training at the University of Texas Health Sciences Center at Houston; and fellowship training in Endocrinology and Metabolism at the Johns Hopkins University School of Medicine in Baltimore, MD.

He serve as an Associate Editor of the Journal of Gerontology Medical Sciences and is on the editorial board of the Journal of Clinical Endocrinology and Metabolism. He lead the section on Male Reproduction on the Self-Assessment Committee of the Endocrine Society for 6 years and has contributed to the development of the Endocrine Society’s Male Androgen Deficiency Performance Improvement Module. He is also a recipient of several teaching awards and provides high-quality care for his patients in the Male Reproduction Clinic at the Brigham and Women’s Hospital.

Prof Chris Byrne trained as a clinical scientist in the UK and the US, at Cardiff, Cambridge and Stanford Universities. He undertook a PhD studying liver lipid metabolism at Cambridge University. Chris was a post-doctoral fellow at Stanford University and then an MRC fellow at Cambridge University. He was appointed to the Chair of Endocrinology & Metabolism at the University of Southampton in 1999, and was also inaugural Director of the Wellcome Trust Clinical Research Facility at Southampton. He is currently Principal Investigator within the National Institute for Health Research Southampton Biomedical Research Centre. Chris undertakes research on the aetiology, pathogenesis and treatment of non alcoholic fatty liver disease (NAFLD) and specialises in caring for patients with diabetes and NAFLD. He collaborates with many researchers from around the globe, and has published over 270 publications related to metabolic syndrome and NAFLD. He was a former recipient of the Dorothy Hodgkin prize awarded by Diabetes UK, for internationally-recognised research excellence related to diabetes.

Prof. Annamaria Colao is a Full Professor of Endocrinology at the Universita' Federico II di Napoli. She studied medicine from 1977 to 1983 at the same university. She was a fellow in Pituitary Physiopathology mentored by Prof. G. Lombardi from 1981-1986. She graduated in Endocrinology and Metabolic Diseases Magna cum Laude discussing a thesis on inferior petrosal sinus sampling in 1986 and received her PhD PhD fellow in Endocrinological and Metabolic Sciences at the Department of Molecular Pathology, University "Federico II" of Naples in 1991. She was Chair of the Unit of Endocrinology of the “Federico II” University of Naples. She is also the Chair of the Health Care Provider University Hospital “Federico II” for Rare Endocrine Diseases granted from the Italian Minister of Health.

She was appointed as the Italian Coordinator of the Endocrine Reference Network for the European Commission for rare diseases ENDO-ERN. She is Chair of the Excellence European Center for Neuroendocrine Tumors granted by the European Society of Neuroendocrine Tumors and the Excellence National Center for Obesity (C.I.B.O.) granted by the Italian Society of Obesity.

She is a member of number councils such as the CNGR (Comitato Nazionale Garanti per la Ricerca) National Committee for Research from April 2012-April 2015, President of the CNGR (Comitato Nazionale Garanti per la Ricerca) National Committee for Research from April 2015-April 2016, Administrative Council of the II University of Naples (now University Vanvitelli of Campania) from 2013-2017 and the Administrative Council of the Italian Institute of Technology 2017 until present.

She has characterized scientific activities by publication of more than 800 full papers in international journals (IF 3139), more than 100 chapters in books, monografies, books; and has made 40439 citations.

Gordon Francis is a physician scientist and Professor of Medicine (Endocrinology and Metabolism) at the University of British Columbia in Vancouver, Canada. He has published more than 100 peer reviewed publications and book chapters primarily in the areas of lipid metabolism, high density lipoproteins, intracellular cholesterol transport and efflux, clinical lipid management, and recently the role of smooth muscle cells in foam cell formation in atherosclerotic plaque. Clinically he is Director of the Healthy Heart Program Prevention/Lipid Clinic based at St. Paul’s Hospital, one of the largest clinics for lipid disorders and cardiovascular risk reduction in Canada. He is a member of the Canadian Cardiovascular Society Guidelines panel for the management of dyslipidemia, recently advocating for the use of non-HDL-cholesterol as an alternate treatment target, and the use of nonfasting testing for screening and follow up of lipid levels. As a clinical lipidologist he has participated in many clinical trials of novel lipid-lowering therapies.

Professor Desmond Johnston is the head of the Diabetes Endocrinology and Metabolism Section within the Department of Medicine. His section is involved in several clinical and laboratory based research investigating early changes in insulin secretion, insulin sensitivity and other aspects of metabolism in people predisposed to Type 2 diabetes before diabetes develops. He is also interested in the mechanisms underlying the premature vascular disease to which people with diabetes are prone and in associated metabolic disturbances.

He is also the Vice Dean for Education in the Department of Medicine at Imperial College London. His role includes responsibility for medical education and activities related to the Lee Kong Chian School of Medicine – a joint initiative between Imperial College London and Nanyang Technological University in Singapore.

He joined the St Mary’s Hospital Medical School in 1986 and is a former Chief of Service (Specialist & Elderly Medicine) in the Imperial College Healthcare NHS Trust. He is a trained clinician and is actively involved in diabetes and metabolic medicine clinics.

Bryan R. Haugen, MD is Professor of Medicine and Pathology at the University of Colorado School of Medicine and a member of the University of Colorado Cancer Center. He is also Chief of the Division of Endocrinology, Metabolism & Diabetes and Director of the Thyroid Tumor Program which provides care for more than 3000 patients with thyroid cancer. He currently holds the Mary Rossick Kern and Jerome H Kern Chair in Endocrine Neoplasms Research. Dr Haugen received is BA degree in Chemistry from Saint Olaf College and medical degree from the Mayo Medical School in 1987. Internship, medical residency and endocrine fellowship were completed at the University of Colorado Health Sciences Center. Dr Haugen is a Fellow in the American College of Physicians, and member of the Association of American Physicians (AAP). Dr Haugen was President of the American Thyroid Association (ATA) 2012-2013 and Chair of the ATA thyroid nodule and differentiated cancer guidelines task force which published the guidelines in Jan 2016. He has received the Paul Starr Award from the ATA for advancements in clinical thyroidology. His current clinical interests include thyroid neoplasms, advanced thyroid cancer, thyroid dysfunction and other endocrine tumors (parathyroid, adrenal, carcinoid). Dr Haugen’s research interests include molecular studies of thyroid neoplasm diagnosis and pathophysiology as well as the study of molecular therapeutic targets. He is currently PI of 2 NCI R01 grants to study mechanisms and therapeutic targets in advanced thyroid cancer. Dr Haugen led validation of a novel molecular test (called Afirma, marketed by Veracyte, Inc) that can help avoid unnecessary surgery in certain patients with thyroid nodules. His research group is also actively studying the individual host-tumor interaction in thyroid cancer to develop novel tumor immunology tests and therapies.

Dr Haugen has had a great interest in caring for patients with thyroid cancer and helping to find better treatments and management strategies for these patients for more than 20 years.

Dr. Al Kaabi obtained the basic medical science degree from the University of St. Andrews Scotland in 1990 and the Medical Degree from University of Manchester- England in 1993. Subsequently trained in Internal Medicine in the United Kingdom followed by Clinical Fellowship in Endocrinology and Metabolism at the University of Alberta, Edmonton, Canada where he spent two years and a half as clinical fellow at the department of Endocrinology and Metabolism and was attached to the islet cell transplant unit. In his current clinical position, he providies comprehensive ambulatory setting and consultative service in General Internal Medicine, Endocrinology, Diabetes and Metabolism. Since his return home, Dr Al Kaabi has made significant contributions into the clinical healthcare system of the UAE through his membership of the Ministry of Health National Diabetes Committee. In the community, he made the speciality of diabetes reachable and understandable by the general population to direct involvement with national guidelines preparations and awareness campaigns. He has been active in contributing to the CME, public health awareness in the community. In addition, he has been successful in organising the Annual Diabetes Workshops in the Faculty of Medicine UAE University and has been a member of the scientific committee for many local conferences, workshops and scientific meetings. . He has been elected recently as member of the board of directors of the Gulf Chapter of the American Association of Clinical Endocrinologists.

COMING SOON

Prof. Sally Marshall was educated at University of Glasgow (BSc 1975, MB 1978, MD1990).

She is currently, Professor of Diabetes, Institute of Cellular Medicine, Newcastle University and Consultant Physician, Newcastle upon Tyne Hospitals NHS Trust.

Her research interests are in diabetes and the kidney, particularly the natural history, genetics and the links with cardiovascular disease and hypertension. Lead diabetes clinician for management of cystic fibrosis related diabetes.

Helen Murphy is a Professor of Medicine (Diabetes and Antenatal Care) at the University of East Anglia and Professor of Women’s Health at Kings College London. She is also an honorary consultant physician at Cambridge University NHS Foundation Trust since 2006.

Helen runs a diabetes pregnancy research programme which aims to improve the glucose control and infant health outcomes of pregnant women with diabetes. Her research interests include improving access to preconception care, developing novel continuous glucose monitoring and artificial pancreas technologies and the role of maternal dietary intake in gestational diabetes. She supervises higher degree students from diabetes & endocrinology, clinical biochemistry and obstetrics & gynaecology. Her research is funded by the National Institute for Health Research (NIHR), Juvenile Diabetes Research Foundation (JDRF), Diabetes UK, Diabetes Research & Wellness Foundation (DRWF), and European Association for the Study of Diabetes (EASD).

Dr Ebaa Al-Ozairi is an assistant professor at Kuwait University and a specialist in diabetes and endocrinology at Mubarak Al-Kabeer hospital. She graduated from Aberdeen University (UK) and has completed her full postgraduate program in Diabetes and Endocrinology from Newcastle University, UK. She was awarded Fulbright fellowship to Joslin Diabetes Center, Harvard medical school.

Her research interest includes diabetes education, obesity, bariatric surgery, and diabetes in young people. Dr Ebaa Al-Ozairi has been accredited by the Royal College of physician as an educator and is an associate practitioner at the UK higher National Academy. Within Kuwait diabetes team, Dr Ebaa considers herself as diabetes friends.

Yousef Saleh graduated in 1991 from King Saud University in Riyadh, Saudi Arabia. He completed 3 years of residency training in Internal Medicine at King Faisal Specialist hospital and King Abdulaziz Medical City (KAMC) in Riyadh. He completed the Membership of The Royal College of Physicians (London), MRCP (U.K.) in 1994 and the Arab Board of Medicine in 1996. Subsequently he did his Fellowship Training in Endocrinology and Diabetes at The University of California, San Diego in 1997 - 1998. He re-joined KAMC as Consultant of Medicine and Endocrinology since then.

He was appointed as Assistant Professor of Medicine and Endocrinology, King Saud University for Health Sciences in 2009 and was promoted to Associate Professor in 2016.

Dr Saleh is currently the Head Division of Adult Endocrinology at the Department of Medicine, King Abdulaziz Medical City in Riyadh, Saudi Arabia.

He chaired the Saudi Board of Medicine and Medical Subspecialties at the Saudi Commission for Health Specialties between 2011 and early 2017.

Dr Saleh is currently the Vice President of the Saudi Osteoporosis Society and board member of AACE, Gulf Chapter. He is the co-establisher of the Saudi Fellowship Training Program of Diabetes in Saudi Arabia launched in March 2016.

He has more than 37 publications in peer reviewed journals in the field of diabetes and endocrinology particularly on aspects of Diabetes, Metabolic Syndrome, osteoporosis and Vitamin D in Saudi Arabia. He published the first ever Saudi National Guidelines for Osteoporosis and is the 2nd author of the Saudi Guidelines for Vitamin D.

Dr. Nasreen Al-Sayed graduated from Arabian Gulf University, college of Medicine in Bahrain. She is American Board Certified. She completed her residency training in Internal medicine at Sinai-Grace Hospital, Wayne State University, Detroit, Michigan, USA and Fellowship training in Endocrinology and Diabetes at Cleveland Clinic Foundation, Ohio, and USA. Dr. Al-Sayed is also American Board Certified in Clinical Lipidology and is the first physician to have board certification in lipids in Middle East. Dr. Al-Sayed is a fellow of American College of Physicians. She is a member of many Diabetes and Endocrine Associations such as the American Diabetes Association, the American Association of Clinical Endocrinologists, The American College of Physicians, The National Lipid Association and has several research publications. Dr. Al-Sayed has a special interest in clinical diabetes, thyroid disorders, parathyroid disorders, osteoporosis, pituitary disorders, adrenal disorders, polycystic ovary syndrome and hirsutism. She is first physician in Middle East with experience in treating resistant cases of hyperparathyroidism with parathyroid hormone. She has also teaching experience and served as an Assistant Professor at Arabian Gulf University, College of Medicine & Medical Sciences.

Dr. Khalid Al Waili was born in Oman. He studied medicine in Oman and obtained his Medical Degree in 2001. Dr. Al Waili got his training in Medical Biochemistry at McGill University in Canada 2009. Then he spent two years in Canada, working as a fellow and Scientist in clinical Lipidology at the Royal Victoria Hospital, University of Canada, under the direct supervision of Prof. Jacques Genest, MD. There he was able to perform a number of studies on the molecular genetics of familial hypercholesterolemia and hypoalphalipoproteinemia. In that period Dr. Al Waili also received strong training in the Lipid Clinic of the Royal Victoria Hospital University of McGill, under the direct supervision of Prof. Jacques Genest, MD from 2009-2010. The National Lipid Association in the United States also awarded him a certificate in Clinical Lipidology in 2010.

Dr. Al Waili is a Senior Consultant at the Sultan Qaboos University Hospital (SQUH) and he is the Deputy Head of Department of Biochemistry at the Sultan Qaboos University Hospital (SQUH) in Oman. Moreover, he is a member of the Unit of Lipid and LDL-Apheresis at SQUH. Dr. Al Waili is a founder of Lipid & Atherosclerosis (OSLA) in 2012. In addition, he was trying to improve the recognition of OSLA as an active society nationally and internationally as a key player in promoting scientific education and general awareness relating to lipid disorders and atherosclerosis through mini-conferences, organization of plenary lectures delivered by veritable experts in the field of Lipid research, as well as public outreach activities.

Dr. Al Waili is a member of national and international medical associations. He has several publication and one chapter book in the field of lipid and atherosclerosis.

Dr. Young is Professor of Medicine in the Mayo Clinic College of Medicine. He is a Past President of the American Endocrine Society and Past Chair of the American Board of Internal Medicine Specialty Board in Endocrinology. Dr. Young has published more than 250 articles on endocrine hypertension and adrenal and pituitary disorders. He has been the recipient of multiple education awards and has presented at more than 500 national and international meetings.

Dr. Ali S. Alzahrani is a Professor of Medicine and Endocrinology at Al Faisal University in Riyadh. Dr. Ali Zahrani obtained his Medical Degree from King Saud University in 1990. This was followed by Residency in Internal Medicine at KFSH & RC during the period 1991-1995 and Clinical and Research Fellowship at the John Hopkins School of Medicine in Baltimore, USA during the years 1995-1998. He has been a Consultant Endocrinologist at KFSH & RC since 1998. During the period 2010 to 2011, Dr. Alzahrani was a faculty member and visiting Scientist at the Division of Endocrinology and Metabolism in John Hopkins University, School of Medicine, Baltimore, United States of America. Since his return late in 2011, he has become a Scientist and Head of the Molecular Endocrinology Division in the Department of Molecular Oncology, Research Center in addition to his Consultant Endocrinology position. Most recently, he has been appointed as a Deputy Executive Director, Research Center at KFSH & RC, Jeddah.

Dr. Alzahrani is proactive in several editorial boards of famously known medical publications. He was the Editor-in Chief of the Annals of Saudi Medicine and an Editorial Board Member of the British Journal of Diabetes and Vascular Medicine. He is an Editorial Board member of the prestigious official journal of the American Thyroid Association, THYROID. Dr. Alzahrani has more than 70 peer-reviewed articles, more than ninty regional and international presentations and has conducted more than ninety lectures nationally and internationally as an invited speaker. Dr. Al Zahrani’s academic interests are clinical and molecular research in the areas of thyroid cancer and endocrine genetics.